开元官网登录入口

Shanghai, China - On November 2, 2022, following the completion of 300 clinical validation surgeries assisted by the MicroPort^® Toumai^® Laparoscopic Surgical Robot, the Honghu Orthopedic Surgical Robot (hereinafter referred to as “Honghu”), independently developed by MicroPort NaviBot (Suzhou) Co., Ltd (hereinafter referred to as “MicroPort^® NaviBot^® (Suzhou)”), the holding subsidiary of Shanghai MicroPort MedBot (Group) Co., Ltd. (hereinafter referred to as “MicroPort^® MedBot^®”), completed the same number of robot-assisted clinical validation surgeries in departments of orthopedics, joint surgery, and sports medicine in 27 hospitals, spanning 18 cities in seven provinces nationwide, accompanied by training provided for more than 140 surgeons on how to perform robot-assisted surgeries. It is a sign that MicroPort^® Honghuhas become increasingly sophisticated in clinical application with its highly stable performance, thereby fully meeting the clinical requirements of orthopedic surgical robots to empower hospitals to achieve high-quality growth.

As a trailblazer of medical robotics in China, MicroPort^® MedBot^® has spent years developing the Honghu Orthopedic Surgical Robot, which is the first and only Chinese-developed orthopedic surgical robot that has been approved by the NMPA and the FDA for marketing. Honghuhas continuously risen to the challenge of complicated surgical procedures, and assisted clinical experts to achievemany breakthroughs, demonstrating its excellent value in clinical application. Honghu, with its outstanding strength in advanced technologies and impressive surgical records continuously made, has accelerated the realization of the national strategy of “localization of high-end medical devices”.

The 300 clinical validation surgeries completed by Honghu include multiple first and difficult robot-assisted surgeries, such as the first 5G remote joint replacement surgery with the help of the Chinese-developed surgical robot, the joint replacement surgery after the internal fixation of an intramedullary nail due to the femoral shaft fracture, and the joint replacement surgery for severe rheumatoid arthritis, assisting experts to achieve multiple “firsts” with the help of Chinese-developed robots and manifesting Honghu s high clinical application value based on its precise operation, efficient collaboration, safety protection, and strong compatibility.

These challenging surgeries have continuously verified the ability of the Chinese-developed Honghu Orthopedic Surgical Robot to meet diverse clinical requirements and it has become a powerful tool of clinical experts thanks to its technical prowess to perform complicated surgeries. Meanwhile, the 5G remote surgery and the “Honghu - Journey to Yunnan” mirror the confidence and determination of MicroPort^® MedBot^® to enable quality medical resources to reach more areas, so that patients can have access to high-end, affordable medical services and intelligent surgical solutions.

On September 17, 2021, the HonghuOrthopedic Surgical Robot successfully completed the first Chinese-developed robot-assisted joint replacement surgery via the 5G technology. The surgery was performed by the team led by Prof. Huiwu Li from the Orthopedics Department of Shanghai Ninth People’s Hospital affiliated to Shanghai JiaoTong University School of Medicine at the headquarters of MicroPort^® MedBot^® through a 5G platform, interconnecting with Prof. Chuan Li’s team from the Orthopedics Department of the 920 Hospital of the People’s Liberation Army Joint Logistic Support Force and Prof. Haobo Zhong’s team from the Orthopedics Department of the Huizhou First Hospital in Guangdong Province, marking a new milestone for MicroPort^® MedBot^® in the realm of intelligent surgery applications by allowing high-quality medical resources, with the technological empowerment, to reach more remote areas for the benefit of more patients.

On September 17, 2021, Honghuperformed a robotic-assisted total knee replacement surgery for an 85-year-old woman after the internal fixation of an intramedullary nail for a femoral stem fracture. Due to the intramedullary nail already placed in the body after a fracture of femoral shaft, the total knee replacement cannot be achieved via a conventional surgery. The robotic total knee replacement assisted the surgeon in developing a personalized prosthesis implantation plan on the basis of the patient’s preoperative CT scan and prosthesis model data. During the operation, through a precise positioning of surgical planning, a quick osteotomy can be realized based on the alignment technology as well as self-developed highly flexible and lightweight robotic arms, so that surgeons can operate in a precise, secure, and efficient manner. Furthermore, it can avoid the medullary positioning in traditional surgeries and there is no intraoperative rod implantation, which can reduce surgical injury and bleeding, improve postoperative lower limb force lines, lessen complications, and help patients have a quicker recovery.

On January 17, 2022, a robotic-assisted total knee replacement surgery was smoothly performed with the help of Honghu on a 53-year-old woman with severe rheumatoid arthritis. The successful completion of challenging surgeries expanded the scope of clinical procedures of Honghu and greatly boosted operators’ morale when operating with Chinese-developed orthopedic surgical robots.

From January 17 to March 14, 2022, Honghu embarked on a tour to Yunnan, serving 14 hospitals in nine prefecture-level cities by starting from Dali, passing through Chuxiong and Kunming, and going all the way to Zhaotong and Diqing in the north, Pu’er and Honghe in the south, Qujing in the east, as well as Nujiang in the west, during which nearly 30 local surgeons received training on how to operate Honghu in surgeries and 50 patients underwent knee replacement with the help of the Honghu Orthopedic Surgical Robot. “Honghu- Journey to Yunnan” aims to fulfill the social responsibility of a Chinese-developed medical device company by helping surgeons better shoulder their responsibility of treating patients and removing people’s sufferings to regain their health as soon as possible.

The successful completion of 300 clinical validation surgeries fully demonstrates that the reliable and stable performance of Honghuenables it to handle difficult clinical tasks. Honghuempowers the surgeon’s “hands” (robotic arms), “eyes” (navigation), and “brain” (intelligent planning) in a digital manner, thereby effectively addressing the clinical bottlenecks of over-dependence on the surgeon’s experience, and the inability to achieve standardization and reproducibility.

At the same time, the MicroPort^® MedBot^® team provides professional and efficient one-stop services including clinical training, customer services, and clinical support, and comprehensively popularizes high-quality medical resources to be available in more areas via innovative robotic surgery teaching demonstration modes such as the 5G interconnectivity platform. While benefiting more patients, it can help hospitals at all levels improve surgical efficiency and ward turnover, thus enhancing robotic medical care and service value of hospitals.

Dr. Yangbin Chen, General Manager of MicroPort^® NaviBot^® (Suzhou), said, “2022 is destined to be a meaningful year for Honghu, since the Honghu Orthopedic Surgical Robot received FDA approval in the second half of the year to become the first Chinese-developed robot to be marketed in the U.S., and has completed 300 clinical surgeries up to now. Such feat marks that Honghu has not only been acclaimed by international authoritative medical institutions, but is also getting increasingly sophisticated in clinical application by taking the lead in handling complicated and difficult surgical procedures to provide surgeons and patients in China with integrated digital orthopedic surgical solutions that are professional, safe, and efficient.

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort^® MedBot^®, said, “The successful completion of 300 operations of Honghu has ushered in a new era of intelligent, precise, and minimally invasive surgeries. As a powerful helper for surgeons, the HonghuOrthopedic Surgical Robot can make every step of intraoperative procedures safe and reliable, so that the root cause can be accurately targeted in accordance with the preoperative plan. MicroPort^® MedBot^® will continue to step up cooperation with clinical experts and keep innovating and upgrading products, in an effort to provide surgeons and patients with high-quality and inclusive robotic-assisted, intelligent total surgical solutions to fulfill the company’s founding aspiration to “Make Surgery Easier, Safer and Less Invasive”.

①The registered trademark of HongHu is named “Skywalker” in abroad , which is in the process of application in USA, completed registration in EU and other countries and regions.